Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$4.09 - $6.43 $28,589 - $44,945
-6,990 Reduced 1.25%
551,010 $2.39 Million
Q2 2023

Aug 14, 2023

BUY
$3.5 - $7.31 $1.95 Million - $4.08 Million
558,000 New
558,000 $3.66 Million

Others Institutions Holding IKNA

About Ikena Oncology, Inc.


  • Ticker IKNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,257,500
  • Market Cap $59.8M
  • Description
  • Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...
More about IKNA
Track This Portfolio

Track Acuta Capital Partners, LLC Portfolio

Follow Acuta Capital Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acuta Capital Partners, LLC with notifications on news.